MX356386B - Sales cuaternarias de piperidinio. - Google Patents
Sales cuaternarias de piperidinio.Info
- Publication number
- MX356386B MX356386B MX2015001769A MX2015001769A MX356386B MX 356386 B MX356386 B MX 356386B MX 2015001769 A MX2015001769 A MX 2015001769A MX 2015001769 A MX2015001769 A MX 2015001769A MX 356386 B MX356386 B MX 356386B
- Authority
- MX
- Mexico
- Prior art keywords
- piperidinium
- quaternary salts
- acetoxy
- propoxy
- diphenyl
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 abstract 2
- -1 piperidinium halides Chemical class 0.000 abstract 2
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681415P | 2012-08-09 | 2012-08-09 | |
| PCT/US2013/052626 WO2014025569A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015001769A MX2015001769A (es) | 2015-05-08 |
| MX356386B true MX356386B (es) | 2018-05-28 |
Family
ID=50068488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001769A MX356386B (es) | 2012-08-09 | 2013-07-30 | Sales cuaternarias de piperidinio. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9896416B2 (https=) |
| EP (1) | EP2882711B1 (https=) |
| JP (1) | JP6345665B2 (https=) |
| KR (2) | KR102240999B1 (https=) |
| CN (2) | CN108658842A (https=) |
| AU (1) | AU2013300009B2 (https=) |
| BR (1) | BR112015002832B1 (https=) |
| CA (1) | CA2881182C (https=) |
| EA (1) | EA029678B9 (https=) |
| HK (1) | HK1211572A1 (https=) |
| IL (1) | IL236996A0 (https=) |
| IN (1) | IN2015DN01018A (https=) |
| MX (1) | MX356386B (https=) |
| WO (1) | WO2014025569A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978201A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| CN114868435B (zh) | 2019-08-22 | 2023-12-26 | 欧芬诺有限责任公司 | 针对多址接入的策略控制 |
| CN117018194B (zh) * | 2023-07-26 | 2026-04-17 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD106643A1 (https=) * | 1973-07-12 | 1974-06-20 | ||
| CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
| DE10129832A1 (de) * | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
| KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
| KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
| EP1713473B1 (en) * | 2004-02-06 | 2013-03-13 | MEDA Pharma GmbH & Co. KG | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| CA2618933C (en) * | 2005-08-12 | 2016-09-20 | Dietmar Plenz | Neuronal avalanche assay |
| CN1951938A (zh) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | 戊乙奎醚季铵盐及其衍生物 |
| SE0600876L (sv) | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| CN101490003A (zh) | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| WO2007123465A1 (en) * | 2006-04-24 | 2007-11-01 | Astrazeneca Ab | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder |
| EP2470504B1 (en) * | 2010-03-15 | 2013-10-16 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
| CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
| EP4035668A1 (en) * | 2012-09-05 | 2022-08-03 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
-
2013
- 2013-07-30 MX MX2015001769A patent/MX356386B/es active IP Right Grant
- 2013-07-30 CA CA2881182A patent/CA2881182C/en active Active
- 2013-07-30 KR KR1020207005139A patent/KR102240999B1/ko not_active Expired - Fee Related
- 2013-07-30 AU AU2013300009A patent/AU2013300009B2/en not_active Ceased
- 2013-07-30 KR KR20157006047A patent/KR20150040355A/ko not_active Ceased
- 2013-07-30 CN CN201810664740.3A patent/CN108658842A/zh active Pending
- 2013-07-30 BR BR112015002832-2A patent/BR112015002832B1/pt not_active IP Right Cessation
- 2013-07-30 EP EP13827594.6A patent/EP2882711B1/en active Active
- 2013-07-30 IN IN1018DEN2015 patent/IN2015DN01018A/en unknown
- 2013-07-30 CN CN201380042085.3A patent/CN104603108A/zh active Pending
- 2013-07-30 JP JP2015526567A patent/JP6345665B2/ja not_active Expired - Fee Related
- 2013-07-30 HK HK15112219.3A patent/HK1211572A1/xx unknown
- 2013-07-30 US US14/419,381 patent/US9896416B2/en not_active Expired - Fee Related
- 2013-07-30 WO PCT/US2013/052626 patent/WO2014025569A1/en not_active Ceased
- 2013-07-30 EA EA201500209A patent/EA029678B9/ru unknown
-
2015
- 2015-01-29 IL IL236996A patent/IL236996A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA029678B1 (ru) | 2018-04-30 |
| HK1211572A1 (en) | 2016-05-27 |
| MX2015001769A (es) | 2015-05-08 |
| KR20150040355A (ko) | 2015-04-14 |
| EP2882711A4 (en) | 2016-02-10 |
| EP2882711B1 (en) | 2017-10-25 |
| KR102240999B1 (ko) | 2021-04-15 |
| JP6345665B2 (ja) | 2018-06-20 |
| US20150203452A1 (en) | 2015-07-23 |
| CN108658842A (zh) | 2018-10-16 |
| EA201500209A1 (ru) | 2015-05-29 |
| EA029678B9 (ru) | 2018-07-31 |
| AU2013300009B2 (en) | 2017-06-15 |
| CA2881182C (en) | 2021-01-26 |
| US9896416B2 (en) | 2018-02-20 |
| WO2014025569A1 (en) | 2014-02-13 |
| EP2882711A1 (en) | 2015-06-17 |
| CA2881182A1 (en) | 2014-02-13 |
| BR112015002832A2 (https=) | 2017-07-04 |
| IL236996A0 (en) | 2015-03-31 |
| AU2013300009A1 (en) | 2015-02-26 |
| KR20200022522A (ko) | 2020-03-03 |
| BR112015002832B1 (pt) | 2022-08-16 |
| IN2015DN01018A (https=) | 2015-06-26 |
| JP2015524469A (ja) | 2015-08-24 |
| CN104603108A (zh) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405101B (en) | "new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them." | |
| WO2016064082A3 (ko) | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 | |
| EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
| IN2015DN03984A (https=) | ||
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| SG10201908582TA (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| GEP201706739B (en) | Compositions comprising vortioxetine and donepezil | |
| UY34730A (es) | Formulaciones farmacéuticas que comprenden antagonistas de ccr3 | |
| PH12014502856A1 (en) | Solid pharmaceutical preparation containing levothyroxine | |
| EP2900272A4 (en) | MISSIBLE PHARMACEUTICAL COMPOSITION WITH KONJAC-GLUCOMANNAN | |
| MX2016008369A (es) | Composicion farmaceutica que incluye palonosetron. | |
| WO2014133744A3 (en) | Oral care compositions | |
| MX356386B (es) | Sales cuaternarias de piperidinio. | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| IL246298A0 (en) | History of piperidine, their preparation and pharmaceutical preparations containing them | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| MX394413B (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma | |
| HK1219723A1 (zh) | 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物 | |
| WO2014115169A3 (en) | Crizotinib solid dispersion | |
| WO2017004172A8 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| WO2014133746A3 (en) | Oral care compositions | |
| LT2953617T (lt) | Farmacinės kompozicijos, apimančios mažų dozių vaistus | |
| AR134057A2 (es) | Composición farmacéutica en solución acuosa | |
| 宋双双 | Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs | |
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |